...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Modulation of antimicrobial potency of human cathelicidin peptides against the ESKAPE pathogens and in vivo efficacy in a murine catheter-associated biofilm model
【24h】

Modulation of antimicrobial potency of human cathelicidin peptides against the ESKAPE pathogens and in vivo efficacy in a murine catheter-associated biofilm model

机译:鼠颈病原体对牛仔植物病原体的抗菌性效力和鼠导管相关生物膜模型的体内疗效

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Antimicrobial peptides are essential components of innate immune systems that protect hosts from infection. They are also useful candidates for developing a new generation of antibiotics to fight antibiotic-resistant pathogens. Human innate immune peptide LL-37 can inhibit biofilm formation, but suffers from high cost due to a long peptide length and rapid protease degradation. To improve the peptide, we previously identified the major active region and changed the peptide backbone structure. This study designed two families of new peptides by altering peptide side chains. Interestingly, these peptides displayed differential potency against various ESKAPE pathogens in vitro and substantially reduced hemolysis. Further potency test in vivo revealed that 17tF-W eliminated the burden of methicillin-resistant Staphylococcus aureus (MRSA) USA300 in both mouse-embedded catheters and their surrounding tissues. In addition, peptide treatment suppressed the level of chemokine TNF alpha, and boosted the levels of chemokines MCP-1, IL-17A and IL-10 in the surrounding tissues of the infected catheter embedded in mice. In conclusion, we have designed a set of new LL-37 peptides with varying antimicrobial activities, opening the door to potential topical treatment of infections involving different drug-resistant pathogens.
机译:抗微生物肽是保护宿主免受感染的先天免疫系统的必要组分。它们也是制定新一代抗生素来对抗抗生素抗性病原体的有用候选者。人体先天免疫肽LL-37可以抑制生物膜形成,但由于长的肽长度和快速蛋白酶降解,患有高成本。为了改善肽,我们之前鉴定了主要的活性区域并改变了肽骨干结构。这项研究通过改变肽侧链设计了两个新肽的家庭。有趣的是,这些肽在体外展示针对各种Eskape病原体的差异效力,并大大降低溶血。体内进一步的效力试验表明,17TF-W消除了甲氧西林耐金黄色葡萄球菌(MRSA)USA300在两种小鼠嵌入导管和周围组织中的负担。此外,肽处理抑制了趋化因子TNFα的水平,并在嵌入小鼠中的感染导管周围组织中提高了趋化因子MCP-1,IL-17a和IL-10的水平。总之,我们设计了一组新的LL-37肽,具有不同的抗菌活性,开门,以潜在的局部治疗涉及不同耐药病原体的感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号